ERBB2 and Hodgkins lymphoma: FDA-approved ADCs like gemtuzumab ozogamicin for acute myeloid leukemia (31, 32), trastuzumab emtansine for chemotherapy-refractory or advanced HER2-positive breast cancer (33, 34), and brentuximab vedotin for recurrent Hodgkin’s lymphoma (35, 36) had been successfully utilized.